Tag: Takeda
Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior...
Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...
Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...
Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...
Interim Results from Ongoing Studies of Brentuximab Vedotin + Nivolumab in...
Multiple presentations evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda*) across a broad range of Hodgkin lymphoma (HL) settings were presented at the 11th International Symposium...
Antibody-drug Conjugates: Technologies and Global Markets
Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new. Due to many technological advances, recognition of appropriate target antigens, success...
Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...
ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...
Takeda and Maverick Therapeutics Develop Novel Biologics Platform to Advance T-Cell...
Maverick Therapeutics, a private start-up biotechnology company that had been solely financed by MPM Capital when it was spun out of its former parent,...
Patient Enrollment in Phase III ECHELON-2 Clinical Trial of Brentuximab Vedotin...
This week, Seattle Genetics and Takeda Pharmaceutical Co. confirmed that enrollment in the ECHELON-2 clinical trial, a global phase III randomized trial evaluating brentuximab vedotin...
ISHL 2016: Seattle Genetics Commits to Improving Hodgkin Lymphoma Treatment
In a pre-conference announcement before the start of 10th International Symposium on Hodgkin Lymphoma (ISHL) taking place at the Gürzenich in Cologne, Germany, October 22-25,...
Takeda and Crescendo Collaborate to Generate Tumor Targeting Drug-conjugates and Immuno-oncology...
Crescendo Biologics, based in Cambridge, UK, the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company announced a global, strategic, multi- target...
INSIGHT-MM Study Designed to Advance Real-world Understanding of Multiple Myeloma
In late Augustus 2016 Takeda Oncology announced that the INSIGHT-MM, the company's global non-interventional, observational multiple myeloma study, is now enrolling patients. The study...
